FDMT News and Press, 4D Molecular Therapeutics Inc. From 05/09/24

2024-05-09 17:49:01 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution 4D Molecular Therapeutics new overweight at Barclays on genetic medicine platform 4D Molecular slips after regulatory up...

Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden enabling advancement into Phase 3 expected by Q1 2025 Interim 24-week landmark analysis from PRISM Phase 2 Population Ext...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that manage...

Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation 4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics...

2024-05-01 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-29 06:36:20 ET Summary 4D Molecular Therapeutics is a biotechnology company that develops genetic medicines using its Therapeutic Vector Evolution platform. The company's pipeline includes promising ophthalmology, pulmonology, and cardiology candidates, with Phase 3 progre...

2024-04-15 12:22:22 ET "We consider the cystic fibrosis and Fabry programs as free options and that validation of additional pipeline assets could provide long- term upside potential," she added. 4D-710, currently in phase 1/2, is the cystic fibrosis candidate, while 4D-310, also in phase 1...

2024-04-15 06:00:04 ET Gena Wang from Barclays issued a price target of $45.00 for FDMT on 2024-04-15 03:43:00. The adjusted price target was set to $45.00. At the time of the announcement, FDMT was trading at $26.35. The overall price target consensus is at $45.40 with ...

2024-04-15 05:30:02 ET Barclays analyst issues OVERWEIGHT recommendation for FDMT on April 15, 2024 03:43AM ET. FDMT was trading at $26.35 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy recommend...